Clinical Trial Update: Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated how non-alcoholic steatohepatitis affects the pharmacokinetics of the radiopharmaceutical Technetium-99m mebrofenin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis

Drugs mentioned

• Technetium-99m mebrofenin (mebrofenin)

Snippet

Sponsor: University of North Carolina, Chapel Hill | Conditions: Non-alcoholic Steatohepatitis | Phase 1 | Status: COMPLETED